Claim Amendments

Claims 1-70 (canceled).

71. **(currently amended)** A compound **or a pharmaceutically acceptable salt thereof, wherein:**

the compound corresponds in structure to ~~**of the**~~ Formula I:



I;

~~**or a pharmaceutically acceptable salt thereof, wherein**~~

the structure:



is a thiazole or isoxazole, wherein:

the thiazole or isoxazole is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, nitro, alkoxy, hydroxyalkyl, **alkylthio** ~~**thioalkyl**~~, amino, alkylamino, arylamino, alkylsulfonamide, acyl, acylamino, alkylsulfone, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, carboxamide, cyano, and $-(CH_2)_mCOR$;

each m is independently zero, 1, or 2;

each R is independently selected from the group consisting of hydroxy, alkoxy, alkyl, amino, and sulfone;

A^1 is selected from the group consisting of:




 , and

 ,

wherein any such substituent is optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, **alkylthio** ~~**thioalkyl**~~, haloalkyl, cyano, amino, alkylamino, halogen, acylamino, sulfonamide, and -COR^4;

X^{10} is CH_2, O, S, SO_2, CO, CF_2, or $C(CH_3)_2$;

X^{11} is CH_2, O, S, SO_2, CO, CF_2, or $C(CH_3)_2$;

X^{12} is CH_2, O, S, SO_2, CO, or $C(CH_3)_2$;

R^{10} is H, CH_3, OCH_3, **or** OH~~; , or NR_2;~~

R^{11} is H, CH_3, OCH_3, **or** OH~~; , or NR_2;~~

R^{12} is H, CH_3, OCH_3, or OH;

each R^4 is independently hydroxy, alkoxy, alkyl, or amino;

~~as to Z_1 and Z_2:~~

Z_1 is selected from the group consisting of CH_2, O, CH_2O, NH, CO, S, SO, CH(OH), and SO_2; **[[and]]**

Z_2 is a 1-5 carbon linker optionally containing one or more heteroatoms independently selected from the group consisting of O, S, and N;

~~or Z_1-Z_2 contains a moiety selected from the group consisting of carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, and acyl; or Z_1-Z_2 contains a 5- or 6-membered aryl or heteroaryl ring, wherein: the heteroaryl ring optionally is substituted with R^e, and the heteroaryl ring contains 1-3 heteroatoms independently selected from the group consisting of O, N, and S;~~

each R^c is independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, alkoxy, carboxamide, and cyano;

any [[the]] carbon and nitrogen atoms of Z_1 **and [[-]]** Z_2 are optionally substituted by a moiety selected from the group consisting of alkyl, alkoxy, **alkylthio** ~~**thioalkyl**~~, alkylsulfone, aryl, alkoxyalkyl, hydroxy, alkylamino, heteroaryl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl, and acylamino;

~~as to X and Y: X-Y contains a moiety selected from the group consisting of acyl, alkyl, sulfonyl, amino, ether, thioether, carboxamido, sulfonamido, aminosulfonyl and olefins; or~~

X is selected from the group consisting of -CHR^e-, -NR^f-, -O-, -S-, -SO_2-, and -CO-;

[[and]]

Y is selected from the group consisting of -$(CH_2)_p$-, -CHR^g-, -NR^g-, -CO-, and -SO_2-;

R^e is selected from the group consisting of H, lower alkyl, alkoxy, cycloalkyl, alkoxyalkyl, hydroxy, alkynyl, alkenyl, haloalkyl, **alkylthio** ~~**thioalkyl**~~, and aryl, wherein: ~~**when R^e is hydroxy,**~~

the hydroxy **[[group]]** can optionally form a lactone with the **COR^b of the CH_2COR^b moiety bonded to Y^5;** ~~**carboxylic acid function of the chain;**~~

R^f is selected from the group consisting of H, alkyl, aryl, benzyl, and haloalkyl;

each R^g is independently selected from the group consisting of H, alkyl, haloalkyl, alkoxyalkyl, alkynyl, aryl, heteroaryl, aralkyl, hydroxy, alkoxy, and carboxyalkyl;

p is zero or 1;

as to Y^3, **[[and]]** Y^4**, and Y^5**:

Y^5 is carbon, and Y^3 and Y^4 are independently selected from the group consisting of H, alkyl, haloalkyl, halogen, aryl, arakyl, heteroaralkyl, heteroaryl, alkenes, hydroxyalkyl, and alkyne, wherein:

the alkyl ~~chain is straight or branched and~~ optionally contains one or more moieties independently selected from the group consisting of N, O, S, sulfone, sulfonamide sulfonamide, nitrile, carboxamide, carboalkoxy, **and** **[[or]]** carboxyl, and

the aryl and heteroaryl rings:

are monocyclic or bicylic optionally containing 1-5 heteroatoms, ~~may be saturated or unsaturated,~~ and

may optionally be substituted by one or more R^c substituents;

[[or]]

Y^5 is nitrogen, Y^4 is absent, and Y^3 is selected from the group consisting of H, alkyl, haloalkyl, halogen, aryl, arakyl, heteroaralkyl, heteroaryl, alkenes, hydroxyalkyl, and alkyne, wherein:

the alkyl chain optionally contains one or more moieties independently selected from the group consisting of N, O, S, sulfone, sulfonamide sulfonamide, nitrile, carboxamide, carboalkoxy, and carboxyl, and

the aryl and heteroaryl rings:

are monocyclic or bicylic optionally containing 1-5 heteroatoms, and

may optionally be substituted by one or more R^c substituents;

or

Y^5 is carbon, and Y^3, **[[and]]** Y^4**, and Y^5** together form a 3-8 membered monocyclic or a 7-11 membered bicyclic ring, ~~B such that the compound of Formula I corresponds in structure to formula IA:~~



~~IA,~~

wherein **the** ring: ~~**B: optionally contains one or more double bonds,**~~

optionally contains one or more moieties independently selected from the group consisting of O, NR^g, S, CO, and SO_2, and

optionally is substituted with one or more substituents selected from the group consisting of alkyl, haloalkyl, halogen, haloalkyl, alkoxy, alkyne, cyano, alkylsulfone, sulfonamide, carboalkoxy, and carboxyalkyl;

~~**Y^5 is C or N when Y^3 or Y^4 is H; Y^5 is C when Y^3 and Y^4 are both other than H;**~~

R^b is X_2 - R^h;

X_2 is selected from the group consisting of O, S, and NR^j; and

R^h and R^j are independently selected from the group consisting of H, alkyl, aryl, aralkyl, acyl, and alkoxyalkyl.

72. **(currently amended)** A compound **or salt** according to claim 71, wherein:

X is ~~**$-CH_2-$ $-CHR^e-$; R^e is H**~~;

Y is **a bond** ~~**$-(CH_2)_p-$; p is zero**~~;

Y^5 is a carbon; and

R^b is OH.

73. **(currently amended)** A compound **or a pharmaceutically acceptable salt thereof, wherein:**

the compound corresponds in structure to **[[of]]** the following formula:



~~**or a pharmaceutically acceptable salt thereof, wherein:**~~

the structure:



is a thiazole or isoxazole, wherein:

the thiazole or isoxazole is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, nitro, alkoxy, hydroxyalkyl, **alkylthio** ~~**thioalkyl**~~, amino, alkylamino, arylamino, alkylsulfonamide, acyl, acylamino, alkylsulfone, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, carboxamide, cyano, and $-(CH_2)_mCOR$;

each m is independently zero, 1, or 2;

each R is independently selected from the group consisting of hydroxy, alkoxy, alkyl, amino, and sulfone;

A^1 is selected from the group consisting of:









, and





,

wherein any such substituent is optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, **alkylthio** ~~**thioalkyl**~~, haloalkyl, cyano, amino, alkylamino, halogen, acylamino, sulfonamide, and $-COR^4$;

X^{10} is CH_2, O, S, SO_2, CO, CF_2, or $C(CH_3)_2$;

X^{11} is CH_2, O, S, SO_2, CO, CF_2, or $C(CH_3)_2$;

X^{12} is CH_2, O, S, SO_2, CO, or $C(CH_3)_2$;

R^{10} is H, CH_3, OCH_3, **or** OH; ~~, or NR_2;~~

R^{11} is H, CH_3, OCH_3, **or** OH; ~~, or NR_2;~~

R^{12} is H, CH_3, OCH_3, or OH;

each R^4 is independently hydroxy, alkoxy, alkyl, or amino;

~~as to Z_1 and Z_2:~~

Z_1 is selected from the group consisting of CH_2, O, CH_2O, NH, CO, S, SO, CH(OH), and SO_2; and

Z_2 is a 1-5 carbon linker optionally containing one or more heteroatoms independently selected from the group consisting of O, S, and N; ~~or Z_1-Z_2 contains a moiety selected from the group consisting of carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, and acyl; or Z_1-Z_2 contains a 5- or 6-membered aryl or heteroaryl ring, wherein: the heteroaryl ring optionally is substituted with R^e, and the heteroaryl ring contains 1-3 heteroatoms independently selected from the group consisting of O, N, and S;~~

each R^c is independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, alkoxy, carboxamide, and cyano;

any **[[the]]** carbon and nitrogen atoms of Z_1 **and** **[[-]]** Z_2 are optionally substituted by a moiety selected from the group consisting of alkyl, alkoxy, **alkylthio** ~~thioalkyl~~, alkylsulfone, aryl, alkoxyalkyl, hydroxy, alkylamino, heteroaryl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalky, and acylamino;

Y^3 is selected from the group consisting of H, alkyl, ~~$CH_2B_1R^{20}$~~ $CH_2Z^3R^{20}$, CH_2OH, $C{\equiv}C\text{-}R^{21}$,



,





,












$\underline{Z^3}$ **[[B_1]]** is O, SO_2, S, or CO;

R^{20} is alkyl or aryl;

R^{21} is alkyl, aryl, or alkoxyalkyl;

R^{22} is H, alkyl, OCH_3, OH, halogen, amino, or CN;

R^{23} is H, alkyl, OCH_3, OH, halogen, amino, or CN;

R^{24} is H, alkyl, OCH_3, OH, or halogen;

X^{20} is CH_2 or O;

X^{21} is NH, NCH_3, O, or S; and

Y^4 is selected from the group consisting of H, alkyl, haloalkyl, halogen, aryl, arakyl, heteroaralkyl, heteroaryl, alkenes, hydroxyalkyl, and alkyne, wherein:

the alkyl ~~chain is straight or branched and~~ optionally contains one or more moieties independently selected from the group consisting of N, O, S, sulfone, sulfonamide sulfonamide, nitrile, carboxamide, carboalkoxy, **and** **[[or]]** carboxyl, and

the aryl and heteroaryl rings:

are monocyclic or bicylic optionally containing 1-5 heteroatoms, ~~may be saturated or unsaturated,~~ and

may optionally be substituted by one or more R^c substituents.

74. **(currently amended)** A compound **or a pharmaceutically acceptable salt thereof, wherein:**

the compound corresponds in structure to **[[of]]** the following formula:



~~**or a pharmaceutically acceptable salt thereof, wherein:**~~

the structure:



is a thiazole or isoxazole, wherein:

the thiazole or isoxazole is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, nitro, alkoxy, hydroxyalkyl, **alkylthio** ~~**thioalkyl**~~, amino, alkylamino, arylamino, alkylsulfonamide, acyl, acylamino, alkylsulfone, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, carboxamide, cyano, and $-(CH_2)_mCOR$;

each m is independently zero, 1, or 2;

each R is independently selected from the group consisting of hydroxy, alkoxy, alkyl, amino, and sulfone;

A^1 is selected from the group consisting of:









, and





,

wherein any such substituent is optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, **alkylthio** ~~**thioalkyl**~~, haloalkyl, cyano, amino, alkylamino, halogen, acylamino, sulfonamide, and -COR^4;

X^{10} is CH_2, O, S, SO_2, CO, CF_2, or $C(CH_3)_2$;

X^{11} is CH_2, O, S, SO_2, CO, CF_2, or $C(CH_3)_2$;

X^{12} is CH_2, O, S, SO_2, CO, or $C(CH_3)_2$;

R^{10} is H, CH_3, OCH_3, OH, **or** OH; ~~**, or NR_2;**~~

R^{11} is H, CH_3, OCH_3, OH, **or** OH; ~~**, or NR_2;**~~

R^{12} is H, CH_3, OCH_3, or OH;

each R^4 is independently hydroxy, alkoxy, alkyl, or amino;

~~**as to Z_1 and Z_2:**~~

Z_1 is selected from the group consisting of CH_2, O, CH_2O, NH, CO, S, SO, CH(OH), and SO_2; **[[and]]**

Z_2 is a 1-5 carbon linker optionally containing one or more heteroatoms independently selected from the group consisting of O, S, and N; ~~**or Z_1-Z_2 contains a moiety selected from the group consisting of carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, and acyl; or Z_1-Z_2 contains a 5- or 6-membered aryl or heteroaryl ring, wherein: the heteroaryl ring optionally is substituted with R^e, and the heteroaryl ring contains 1-3 heteroatoms independently selected from the group consisting of O, N, and S;**~~

each R^c is independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, alkoxy, carboxamide, and cyano;

any **[[the]]** carbon and nitrogen atoms of Z_1 **and** **[[-]]** Z_2 are optionally substituted by a moiety selected from the group consisting of alkyl, alkoxy, **alkylthio** ~~**thioalkyl**~~, alkylsulfone, aryl, alkoxyalkyl, hydroxy, alkylamino, heteroaryl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalky, and acylamino;

Y^3 is selected from the group consisting of H, methyl, phenyl, ethyl, propyl, isopropyl, phenylmethoxymethyl,





Y^4 is selected from the group consisting of H, alkyl, haloalkyl, halogen, aryl, arakyl, heteroaralkyl, heteroaryl, alkenes, hydroxyalkyl, and alkyne, wherein:

the alkyl ~~**chain is straight or branched and**~~ optionally contains one or more moieties independently selected from the group consisting of N, O, S, sulfone, sulfonamide sulfonamide, nitrile, carboxamide, carboalkoxy, **[[or]]** **and** carboxyl, and

the aryl and heteroaryl rings:

are monocyclic or bicylic optionally containing 1-5 heteroatoms, ~~**may be saturated or unsaturated,**~~ and

may optionally be substituted by one or more R^c substituents.

75. **(currently amended)** A compound **or salt** according to claim 74, wherein A^1 is:



76. **(previously presented)** A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

(2-{5-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-cyclopropyl)-acetic acid;

3-Phenyl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-Pyridin-3-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-Pyridin-3-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

(2-{3-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-cyclopropyl)-acetic acid;

(2-{4-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-cyclopropyl)-acetic acid;

3-Phenyl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-Pyridin-3-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-Phenyl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-Pyridin-3-yl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid

(2-{5-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-cyclopropyl)-acetic acid;

3-Phenyl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-Pyridin-3-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-3-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-Pyridin-3-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-butyric acid;

(2-{3-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-isoxazol-5-yl}-cyclopropyl)-acetic acid;

(2-{4-[3-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-cyclopropyl)-acetic acid;

3-Phenyl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-Pyridin-3-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

3-Benzo[1,3]dioxol-5-yl-4-{4-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-thiazol-2-yl}-butyric acid;

Phenyl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-(2,3-Dihydro-benzofuran-6-yl)-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-(3-Fluoro-phenyl)-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid;

3-Pyridin-3-yl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid; and

3-Benzo[1,3]dioxol-5-yl-4-{3-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-isoxazol-5-yl}-butyric acid.

77. **(previously presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 71 and a pharmaceutically acceptable carrier.

78. **(previously presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of Claim 76 and a pharmaceutically acceptable carrier.

79. **(currently amended)** A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or salt of Claim 71 and a pharmaceutically acceptable carrier ~~**/or additive**~~ and ~~**optionally**~~ a cytotoxic agent.

80. **(currently amended)** A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or salt of Claim 76 and a pharmaceutically acceptable carrier ~~**/or additive**~~ and ~~**optionally**~~ a cytotoxic agent.

81. **(previously presented)** A method for treating a condition mediated by $\alpha_V\beta_3$ integrin selected from the group consisting of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy and arthritis in a mammal in need of such treatment comprising administering an effective $\alpha_V\beta_3$ inhibiting amount of a compound or salt of Claim 71.

82. **(previously presented)** A method for treating a condition mediated by $\alpha_V\beta_3$ integrin selected from the group consisting of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy and arthritis in a mammal in need of such treatment comprising administering an effective $\alpha_V\beta_3$ inhibiting amount of a compound or salt of claim 76.

Claims 83 and 84 (canceled).

85. **(previously presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 73 and a pharmaceutically acceptable carrier.

86. **(currently amended)** A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or salt of claim 73 and a pharmaceutically acceptable carrier ~~**/or additive**~~ and ~~**optionally**~~ a cytotoxic agent.

87. **(previously presented)** A method for treating a condition mediated by $\alpha_V\beta_3$ integrin selected from the group consisting of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy and arthritis in a mammal in need of such treatment comprising administering an effective $\alpha_V\beta_3$ inhibiting amount of a compound or salt of claim 73.

Claim 88 (canceled).

89. **(previously presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 74 and a pharmaceutically acceptable carrier.

90. **(currently amended)** A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or salt of claim 74 and a pharmaceutically acceptable carrier ~~/or additive~~ and ~~optionally~~ a cytotoxic agent.

91. **(previously presented)** A method for treating a condition mediated by $\alpha_V\beta_3$ integrin selected from the group consisting of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atheroscelorosis, macular degeneration, retinopathy and arthritis in a mammal in need of such treatment comprising administering an effective $\alpha_V\beta_3$ inhibiting amount of a compound or salt of claim 74.

Claim 92 (canceled).

93. **(currently amended)** A compound **or a pharmaceutically acceptable salt thereof, wherein:**

the compound corresponds in structure to ~~**of the**~~ Formula I:



I;

~~**or a pharmaceutically acceptable salt thereof, wherein:**~~

the structure:



is a thiazole or isoxazole, wherein:

the thiazole or isoxazole is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, nitro, alkoxy, hydroxyalkyl, **alkylthio** ~~**thioalkyl**~~, amino, alkylamino, arylamino, alkylsulfonamide, acyl, acylamino, alkylsulfone, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, carboxamide, cyano, and $-(CH_2)_mCOR$;

each m is independently zero, 1, or 2;

each R is independently selected from the group consisting of hydroxy, alkoxy, alkyl, amino, and sulfone;

A^1 is selected from the group consisting of:









, and





,

wherein any such substituent is optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, **alkylthio** ~~**thioalkyl**~~, haloalkyl, cyano, amino, alkylamino, halogen, acylamino, sulfonamide, and $-COR^4$;

X^{10} is CH_2, O, S, SO_2, CO, CF_2, or $C(CH_3)_2$;

X^{11} is CH_2, O, S, SO_2, CO, CF_2, or $C(CH_3)_2$;

X^{12} is CH_2, O, S, SO_2, CO, or $C(CH_3)_2$;

R^{10} is H, CH_3, OCH_3, **or** OH**;** ~~**, or NR_2;**~~

R^{11} is H, CH_3, OCH_3, **or** OH**;** ~~**, or NR_2;**~~

R^{12} is H, CH_3, OCH_3, or OH;

each R^4 is independently hydroxy, alkoxy, alkyl, or amino;

~~**as to Z_1 and Z_2:**~~

Z_1 is selected from the group consisting of CH_2, O, CH_2O, NH, CO, S, SO, CH(OH), and SO_2; and

Z_2 is a 1-5 carbon linker optionally containing one or more heteroatoms independently selected from the group consisting of O, S, and N; ~~**or Z_1-Z_2 contains a moiety selected from the group consisting of carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, and acyl; or Z_1-Z_2 contains a 5- or 6-membered aryl or heteroaryl ring, wherein: the heteroaryl ring optionally is substituted with R^e, and the heteroaryl ring contains 1-3 heteroatoms independently selected from the group consisting of O, N, and S;**~~

each R^c is independently selected from the group consisting of alkyl, haloalkyl, aryl, heteroaryl, halogen, alkoxyalkyl, aminoalkyl, hydroxy, alkoxy, carboxamide, and cyano;

any [[the]] carbon and nitrogen atoms of Z_1 **and [[-]]** Z_2 are optionally substituted by a moiety selected from the group consisting of alkyl, alkoxy, **alkylthio** ~~**thioalkyl**~~, alkylsulfone, aryl, alkoxyalkyl, hydroxy, alkylamino, heteroaryl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl, and acylamino;

Y is selected from the group consisting of $-(CH_2)_p-$, $-CHR^g-$, $-NR^g-$, $-CO-$, and $-SO_2-$;

each R^g is independently selected from the group consisting of H, alkyl, haloalkyl, alkoxyalkyl, alkynyl, aryl, heteroaryl, aralkyl, hydroxy, alkoxy, and carboxyalkyl;

p is zero or 1;

X and Y^3**,** together **with the atom(s) to which they are both bonded,** form a 3-7 membered monocyclic ring**,** ~~**C such that the compound of Formula I corresponds in structure to formula IB**~~:



~~IB,~~

wherein **the** ring: ~~**C: optionally contains one or more double bonds,**~~

optionally contains one or more moieties independently selected from the group consisting of O, NR^g, S, CO, and SO_2, and

optionally is substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, alkoxy, haloalkyl, hydroxyalkyl, and alkoxyalkyl;

as to Y^4 and Y^5:

Y^5 is nitrogen, and Y^4 is absent; or

Y^5 is carbon, and Y^4 is selected from the group consisting of H, alkyl, haloalkyl, halogen, aryl, arakyl, heteroaralkyl, heteroaryl, alkenes, hydroxyalkyl, and alkyne, wherein:

the alkyl ~~**chain is straight or branched and**~~ optionally contains one or more moieties independently selected from the group consisting of N, O, S, sulfone, sulfonamide sulfonamide, nitrile, carboxamide, carboalkoxy, **and** **[[or]]** carboxyl, and

the aryl and heteroaryl rings:

are monocyclic or bicylic optionally containing 1-5 heteroatoms,

~~**may be saturated or unsaturated,**~~ and

may optionally be substituted by one or more R^c substituents; or

R^b is X_2 - R^h;

X_2 is selected from the group consisting of O, S, and NR^j; and

R^h and R^j are independently selected from the group consisting of H, alkyl, aryl, aralkyl, acyl, and alkoxyalkyl.

94. **(previously presented)** A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 93 and a pharmaceutically acceptable carrier.

95. **(currently amended)** A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or salt of claim 93 and a pharmaceutically acceptable carrier ~~**/or additive**~~ and ~~**optionally**~~ a cytotoxic agent.

96. **(previously presented)** A method for treating a condition mediated by $\alpha_V\beta_3$ integrin selected from the group consisting of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atheroscelorosis, macular degeneration, retinopathy and arthritis in a mammal in need of such treatment comprising administering an effective $\alpha_V\beta_3$ inhibiting amount of a compound or salt of claim 93.

Claim 97 (canceled).